Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-128800 in relapsing-remitting multiple sclerosis
NCT01006265Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2009
- Primary completion
- Jun 2011
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 23
01
Overview
A Phase 2 trial of ponesimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Actelion Pharmaceuticals Ltd. Started Oct 2009; status: completed.
02
Drugs
ponesimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01006265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01006265.